Report Thumbnail
Product Code LP09143134864WH
Published Date 2024/5/18
English143 PagesGlobal

Global Exosome Therapeutics and Diagnostics Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP09143134864WH◆The May 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/5/18
English 143 PagesGlobal

Global Exosome Therapeutics and Diagnostics Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

Exosomes are small vesicles secreted by cells, which contain biomolecules such as proteins, nucleic acids, and lipids. In recent years, exosomes have attracted much attention due to their role in intercellular communication, disease occurrence and development, etc. The application of exosomes in treatment and diagnosis has also gradually attracted attention.
The global Exosome Therapeutics and Diagnostics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Exosome Therapeutics and Diagnostics Industry Forecast” looks at past sales and reviews total world Exosome Therapeutics and Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Exosome Therapeutics and Diagnostics sales for 2023 through 2029. With Exosome Therapeutics and Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Exosome Therapeutics and Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Exosome Therapeutics and Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Exosome Therapeutics and Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Exosome Therapeutics and Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Exosome Therapeutics and Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Exosome Therapeutics and Diagnostics.
United States market for Exosome Therapeutics and Diagnostics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Exosome Therapeutics and Diagnostics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Exosome Therapeutics and Diagnostics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Exosome Therapeutics and Diagnostics players cover Evox Therapeutics, Carmine Therapeutics, Exopharm, Aruna Bio, Capricor Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Exosome Therapeutics and Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Treatment
Diagnosis
Segmentation by Application:
Cancer
Neurological Diseases
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Treatment
Diagnosis
Segmentation by Application:
Cancer
Neurological Diseases
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Evox Therapeutics
Carmine Therapeutics
Exopharm
Aruna Bio
Capricor Therapeutics
Mantra Bio
Adipomics
ReNeuron
Aegle Therapeutics
Sarepta Therapeutics
Codiak Biosciences
Exosomics
Innocan Pharma
Aethlon Medical
ExoCoBio
Organicell
Puretech
Versatope
Vesvigen Therapeutics
Exosome Plus
Exosome Diagnostics
ECHO Biaotech

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Exosome Therapeutics and Diagnostics Market Size 2019-2030
      • 2.1.2 Exosome Therapeutics and Diagnostics Market Size CAGR by Region (2019 VS 2023 VS 2030)
      • 2.1.3 World Current & Future Analysis for Exosome Therapeutics and Diagnostics by Country/Region, 2019, 2023 & 2030
    • 2.2 Exosome Therapeutics and Diagnostics Segment by Type
      • 2.2.1 Treatment
      • 2.2.2 Diagnosis
    • 2.3 Exosome Therapeutics and Diagnostics Market Size by Type
      • 2.3.1 Exosome Therapeutics and Diagnostics Market Size CAGR by Type (2019 VS 2023 VS 2030)
      • 2.3.2 Global Exosome Therapeutics and Diagnostics Market Size Market Share by Type (2019-2024)
    • 2.4 Exosome Therapeutics and Diagnostics Segment by Application
      • 2.4.1 Cancer
      • 2.4.2 Neurological Diseases
      • 2.4.3 Others
    • 2.5 Exosome Therapeutics and Diagnostics Market Size by Application
      • 2.5.1 Exosome Therapeutics and Diagnostics Market Size CAGR by Application (2019 VS 2023 VS 2030)
      • 2.5.2 Global Exosome Therapeutics and Diagnostics Market Size Market Share by Application (2019-2024)
  • 3 Exosome Therapeutics and Diagnostics Market Size by Player

    • 3.1 Exosome Therapeutics and Diagnostics Market Size Market Share by Player
      • 3.1.1 Global Exosome Therapeutics and Diagnostics Revenue by Player (2019-2024)
      • 3.1.2 Global Exosome Therapeutics and Diagnostics Revenue Market Share by Player (2019-2024)
    • 3.2 Global Exosome Therapeutics and Diagnostics Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Exosome Therapeutics and Diagnostics by Region

    • 4.1 Exosome Therapeutics and Diagnostics Market Size by Region (2019-2024)
    • 4.2 Global Exosome Therapeutics and Diagnostics Annual Revenue by Country/Region (2019-2024)
    • 4.3 Americas Exosome Therapeutics and Diagnostics Market Size Growth (2019-2024)
    • 4.4 APAC Exosome Therapeutics and Diagnostics Market Size Growth (2019-2024)
    • 4.5 Europe Exosome Therapeutics and Diagnostics Market Size Growth (2019-2024)
    • 4.6 Middle East & Africa Exosome Therapeutics and Diagnostics Market Size Growth (2019-2024)
  • 5 Americas

    • 5.1 Americas Exosome Therapeutics and Diagnostics Market Size by Country (2019-2024)
    • 5.2 Americas Exosome Therapeutics and Diagnostics Market Size by Type (2019-2024)
    • 5.3 Americas Exosome Therapeutics and Diagnostics Market Size by Application (2019-2024)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Exosome Therapeutics and Diagnostics Market Size by Region (2019-2024)
    • 6.2 APAC Exosome Therapeutics and Diagnostics Market Size by Type (2019-2024)
    • 6.3 APAC Exosome Therapeutics and Diagnostics Market Size by Application (2019-2024)
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Exosome Therapeutics and Diagnostics Market Size by Country (2019-2024)
    • 7.2 Europe Exosome Therapeutics and Diagnostics Market Size by Type (2019-2024)
    • 7.3 Europe Exosome Therapeutics and Diagnostics Market Size by Application (2019-2024)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Exosome Therapeutics and Diagnostics by Region (2019-2024)
    • 8.2 Middle East & Africa Exosome Therapeutics and Diagnostics Market Size by Type (2019-2024)
    • 8.3 Middle East & Africa Exosome Therapeutics and Diagnostics Market Size by Application (2019-2024)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Exosome Therapeutics and Diagnostics Market Forecast

    • 10.1 Global Exosome Therapeutics and Diagnostics Forecast by Region (2025-2030)
      • 10.1.1 Global Exosome Therapeutics and Diagnostics Forecast by Region (2025-2030)
      • 10.1.2 Americas Exosome Therapeutics and Diagnostics Forecast
      • 10.1.3 APAC Exosome Therapeutics and Diagnostics Forecast
      • 10.1.4 Europe Exosome Therapeutics and Diagnostics Forecast
      • 10.1.5 Middle East & Africa Exosome Therapeutics and Diagnostics Forecast
    • 10.2 Americas Exosome Therapeutics and Diagnostics Forecast by Country (2025-2030)
      • 10.2.1 United States Market Exosome Therapeutics and Diagnostics Forecast
      • 10.2.2 Canada Market Exosome Therapeutics and Diagnostics Forecast
      • 10.2.3 Mexico Market Exosome Therapeutics and Diagnostics Forecast
      • 10.2.4 Brazil Market Exosome Therapeutics and Diagnostics Forecast
    • 10.3 APAC Exosome Therapeutics and Diagnostics Forecast by Region (2025-2030)
      • 10.3.1 China Exosome Therapeutics and Diagnostics Market Forecast
      • 10.3.2 Japan Market Exosome Therapeutics and Diagnostics Forecast
      • 10.3.3 Korea Market Exosome Therapeutics and Diagnostics Forecast
      • 10.3.4 Southeast Asia Market Exosome Therapeutics and Diagnostics Forecast
      • 10.3.5 India Market Exosome Therapeutics and Diagnostics Forecast
      • 10.3.6 Australia Market Exosome Therapeutics and Diagnostics Forecast
    • 10.4 Europe Exosome Therapeutics and Diagnostics Forecast by Country (2025-2030)
      • 10.4.1 Germany Market Exosome Therapeutics and Diagnostics Forecast
      • 10.4.2 France Market Exosome Therapeutics and Diagnostics Forecast
      • 10.4.3 UK Market Exosome Therapeutics and Diagnostics Forecast
      • 10.4.4 Italy Market Exosome Therapeutics and Diagnostics Forecast
      • 10.4.5 Russia Market Exosome Therapeutics and Diagnostics Forecast
    • 10.5 Middle East & Africa Exosome Therapeutics and Diagnostics Forecast by Region (2025-2030)
      • 10.5.1 Egypt Market Exosome Therapeutics and Diagnostics Forecast
      • 10.5.2 South Africa Market Exosome Therapeutics and Diagnostics Forecast
      • 10.5.3 Israel Market Exosome Therapeutics and Diagnostics Forecast
      • 10.5.4 Turkey Market Exosome Therapeutics and Diagnostics Forecast
    • 10.6 Global Exosome Therapeutics and Diagnostics Forecast by Type (2025-2030)
    • 10.7 Global Exosome Therapeutics and Diagnostics Forecast by Application (2025-2030)
      • 10.7.1 GCC Countries Market Exosome Therapeutics and Diagnostics Forecast
  • 11 Key Players Analysis

    • 11.1 Evox Therapeutics
      • 11.1.1 Evox Therapeutics Company Information
      • 11.1.2 Evox Therapeutics Exosome Therapeutics and Diagnostics Product Offered
      • 11.1.3 Evox Therapeutics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.1.4 Evox Therapeutics Main Business Overview
      • 11.1.5 Evox Therapeutics Latest Developments
    • 11.2 Carmine Therapeutics
      • 11.2.1 Carmine Therapeutics Company Information
      • 11.2.2 Carmine Therapeutics Exosome Therapeutics and Diagnostics Product Offered
      • 11.2.3 Carmine Therapeutics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.2.4 Carmine Therapeutics Main Business Overview
      • 11.2.5 Carmine Therapeutics Latest Developments
    • 11.3 Exopharm
      • 11.3.1 Exopharm Company Information
      • 11.3.2 Exopharm Exosome Therapeutics and Diagnostics Product Offered
      • 11.3.3 Exopharm Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.3.4 Exopharm Main Business Overview
      • 11.3.5 Exopharm Latest Developments
    • 11.4 Aruna Bio
      • 11.4.1 Aruna Bio Company Information
      • 11.4.2 Aruna Bio Exosome Therapeutics and Diagnostics Product Offered
      • 11.4.3 Aruna Bio Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.4.4 Aruna Bio Main Business Overview
      • 11.4.5 Aruna Bio Latest Developments
    • 11.5 Capricor Therapeutics
      • 11.5.1 Capricor Therapeutics Company Information
      • 11.5.2 Capricor Therapeutics Exosome Therapeutics and Diagnostics Product Offered
      • 11.5.3 Capricor Therapeutics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.5.4 Capricor Therapeutics Main Business Overview
      • 11.5.5 Capricor Therapeutics Latest Developments
    • 11.6 Mantra Bio
      • 11.6.1 Mantra Bio Company Information
      • 11.6.2 Mantra Bio Exosome Therapeutics and Diagnostics Product Offered
      • 11.6.3 Mantra Bio Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.6.4 Mantra Bio Main Business Overview
      • 11.6.5 Mantra Bio Latest Developments
    • 11.7 Adipomics
      • 11.7.1 Adipomics Company Information
      • 11.7.2 Adipomics Exosome Therapeutics and Diagnostics Product Offered
      • 11.7.3 Adipomics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.7.4 Adipomics Main Business Overview
      • 11.7.5 Adipomics Latest Developments
    • 11.8 ReNeuron
      • 11.8.1 ReNeuron Company Information
      • 11.8.2 ReNeuron Exosome Therapeutics and Diagnostics Product Offered
      • 11.8.3 ReNeuron Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.8.4 ReNeuron Main Business Overview
      • 11.8.5 ReNeuron Latest Developments
    • 11.9 Aegle Therapeutics
      • 11.9.1 Aegle Therapeutics Company Information
      • 11.9.2 Aegle Therapeutics Exosome Therapeutics and Diagnostics Product Offered
      • 11.9.3 Aegle Therapeutics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.9.4 Aegle Therapeutics Main Business Overview
      • 11.9.5 Aegle Therapeutics Latest Developments
    • 11.10 Sarepta Therapeutics
      • 11.10.1 Sarepta Therapeutics Company Information
      • 11.10.2 Sarepta Therapeutics Exosome Therapeutics and Diagnostics Product Offered
      • 11.10.3 Sarepta Therapeutics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.10.4 Sarepta Therapeutics Main Business Overview
      • 11.10.5 Sarepta Therapeutics Latest Developments
    • 11.11 Codiak Biosciences
      • 11.11.1 Codiak Biosciences Company Information
      • 11.11.2 Codiak Biosciences Exosome Therapeutics and Diagnostics Product Offered
      • 11.11.3 Codiak Biosciences Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.11.4 Codiak Biosciences Main Business Overview
      • 11.11.5 Codiak Biosciences Latest Developments
    • 11.12 Exosomics
      • 11.12.1 Exosomics Company Information
      • 11.12.2 Exosomics Exosome Therapeutics and Diagnostics Product Offered
      • 11.12.3 Exosomics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.12.4 Exosomics Main Business Overview
      • 11.12.5 Exosomics Latest Developments
    • 11.13 Innocan Pharma
      • 11.13.1 Innocan Pharma Company Information
      • 11.13.2 Innocan Pharma Exosome Therapeutics and Diagnostics Product Offered
      • 11.13.3 Innocan Pharma Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.13.4 Innocan Pharma Main Business Overview
      • 11.13.5 Innocan Pharma Latest Developments
    • 11.14 Aethlon Medical
      • 11.14.1 Aethlon Medical Company Information
      • 11.14.2 Aethlon Medical Exosome Therapeutics and Diagnostics Product Offered
      • 11.14.3 Aethlon Medical Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.14.4 Aethlon Medical Main Business Overview
      • 11.14.5 Aethlon Medical Latest Developments
    • 11.15 ExoCoBio
      • 11.15.1 ExoCoBio Company Information
      • 11.15.2 ExoCoBio Exosome Therapeutics and Diagnostics Product Offered
      • 11.15.3 ExoCoBio Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.15.4 ExoCoBio Main Business Overview
      • 11.15.5 ExoCoBio Latest Developments
    • 11.16 Organicell
      • 11.16.1 Organicell Company Information
      • 11.16.2 Organicell Exosome Therapeutics and Diagnostics Product Offered
      • 11.16.3 Organicell Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.16.4 Organicell Main Business Overview
      • 11.16.5 Organicell Latest Developments
    • 11.17 Puretech
      • 11.17.1 Puretech Company Information
      • 11.17.2 Puretech Exosome Therapeutics and Diagnostics Product Offered
      • 11.17.3 Puretech Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.17.4 Puretech Main Business Overview
      • 11.17.5 Puretech Latest Developments
    • 11.18 Versatope
      • 11.18.1 Versatope Company Information
      • 11.18.2 Versatope Exosome Therapeutics and Diagnostics Product Offered
      • 11.18.3 Versatope Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.18.4 Versatope Main Business Overview
      • 11.18.5 Versatope Latest Developments
    • 11.19 Vesvigen Therapeutics
      • 11.19.1 Vesvigen Therapeutics Company Information
      • 11.19.2 Vesvigen Therapeutics Exosome Therapeutics and Diagnostics Product Offered
      • 11.19.3 Vesvigen Therapeutics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.19.4 Vesvigen Therapeutics Main Business Overview
      • 11.19.5 Vesvigen Therapeutics Latest Developments
    • 11.20 Exosome Plus
      • 11.20.1 Exosome Plus Company Information
      • 11.20.2 Exosome Plus Exosome Therapeutics and Diagnostics Product Offered
      • 11.20.3 Exosome Plus Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.20.4 Exosome Plus Main Business Overview
      • 11.20.5 Exosome Plus Latest Developments
    • 11.21 Exosome Diagnostics
      • 11.21.1 Exosome Diagnostics Company Information
      • 11.21.2 Exosome Diagnostics Exosome Therapeutics and Diagnostics Product Offered
      • 11.21.3 Exosome Diagnostics Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.21.4 Exosome Diagnostics Main Business Overview
      • 11.21.5 Exosome Diagnostics Latest Developments
    • 11.22 ECHO Biaotech
      • 11.22.1 ECHO Biaotech Company Information
      • 11.22.2 ECHO Biaotech Exosome Therapeutics and Diagnostics Product Offered
      • 11.22.3 ECHO Biaotech Exosome Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.22.4 ECHO Biaotech Main Business Overview
      • 11.22.5 ECHO Biaotech Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.